On high-speed effervescent tableting lines, L(+)-tartaric acid is selected as the proton-donating component in bicarbonate/carbonate couples because its anhydrous crystal form shows lower moisture uptake than citric acid monohydrate and because the dissolution of the acid in water at 20 °C is 1390 g/L. The gas-generating reaction is C₄H₆O₆ + 2 NaHCO₃ → Na₂C₄H₄O₆ + 2 CO₂ + 2 H₂O; one mole of L(+)-tartaric acid with molecular weight 150.09 g/mol consumes two moles of sodium bicarbonate with total mass 168.02 g/mol, giving a theoretical bicarbonate requirement of 1.119 g per 1.000 g anhydrous acid. Production batches are formulated with 1.05–1.15 times the stoichiometric bicarbonate mass because the terminal solution should have pH 4.5–6.0 and an acidic taste residue is rejected by sensory panel evaluation. Theoretical CO₂ yield is 0.298 L/g acid at 0 °C and 101.325 kPa, or 0.326 L/g at 25 °C. Granulation is conducted as a non-aqueous process: binder solutions based on anhydrous ethanol or isopropanol are added in a high-shear granulator with impeller speed 200–400 rpm and chopper speed 1500–3000 rpm, with jacketed vessel cooling maintained below 25 °C. The granules are dried in a fluid-bed dryer at inlet air temperature 35–45 °C and dew point ≤ -20 °C until residual water measured by Karl Fischer titration under Ph. Eur. 2.5.12 is ≤ 0.2% w/w; lots above 0.3% w/w are rejected for effervescent compression because die-cavity gas evolution causes weight variation and punch-film accumulation. Compression on a rotary tablet press with external lubrication at 10–25 kN produces tablets with breaking hardness 40–80 N; friability is tested under Ph. Eur. 2.9.7 and must remain ≤ 1.0%, while disintegration under Ph. Eur. 2.9.1 is run in 200 mL water at 15–25 °C and must finish within 3 min unless the dossier specifies a shorter interval. Primary packaging for finished tablets is typically an aluminium tube with a desiccant cap or an HDPE container with an induction seal and 1–3 g silica gel pouch, based on stability data at 25 °C/60% RH and 40 °C/75% RH. Finished products containing this acid in effervescent form include effervescent acetylcysteine tablets, effervescent vitamin C granules, and effervescent calcium gluconate tablets; in these products the acid contributes both the CO₂ source and the solubilisation of basic drug salts.

Parameter	Control range / specification	Method / equipment
Molecular weight	150.09 g/mol	compendial monograph
Sodium bicarbonate per gram acid	1.05–1.15 g	mass balance
Theoretical CO₂ yield at 25 °C	0.326 L/g acid	gas volumetry
Granulator impeller / chopper	200–400 rpm / 1500–3000 rpm	high-shear granulator
Drying inlet air dew point	≤ -20 °C	adsorption dryer
Residual moisture	≤ 0.2% w/w	Ph. Eur. 2.5.12
Final disintegration	≤ 3 min	Ph. Eur. 2.9.1

What Terminal-Sterilisation Constraints Govern Injectable pH Adjustment with L(+)-Tartaric Acid?

Injectable manufacturing lines use L(+)-tartaric acid as an acidic pH adjuster and buffer-forming component when the target product pH falls in the 2.8–4.6 region. The two carboxylate dissociation constants are pKa₁ 3.04 and pKa₂ 4.37 at 25 °C, giving buffering maxima near pH 3.0 and pH 4.4. A 0.1 M aqueous solution of the acid is prepared with Water for Injections meeting bacterial endotoxin limits below 0.25 EU/mL; the solution is passed through a 0.2 μm polyvinylidene difluoride or polyethersulfone sterilising-grade filter before transfer to a stainless steel 316L formulation vessel. L(+)-tartaric acid is used at final concentrations of 0.05–0.25% w/v for pH adjustment of small-volume parenterals, but the exact amount is determined by potentiometric titration of the drug substance solution because buffer capacity and pH shift depend on API pKa and concentration. Once the target pH of 3.5–4.5 is reached, osmolality is measured with a freezing-point osmometer and adjusted with sodium chloride to 270–330 mOsmol/kg. Terminal sterilisation at 121.1 °C for 15 min does not significantly degrade L(+)-tartaric acid in neutral or acidic aqueous media; however sterilisation validation per USP <1229.1> and Ph. Eur. 5.1.1 must confirm that no racemisation or browning occurs in the specific formulation, particularly if trace reducing sugars are present. The tartrate anion chelates iron and copper ions, which can reduce transition-metal-catalysed oxidative degradation in parenteral solutions; forced degradation studies under ICH Q1A(R2) and ICH Q2(R1) are required to prove the effect because chelation can also alter the stability of metal-containing actives. A critical incompatibility exists with calcium- or magnesium-containing diluents, such as Ringer’s lactate and Hartmann’s solution, because the tartrate salts of divalent cations are sparingly soluble and can form microprecipitates that fail visible particulate testing under USP <788>. Injectable lines therefore require flushing with 0.9% sodium chloride injection before and after administration when tartrate-buffered products are used with calcium-containing solutions.

Factor	Operating range / specification	Standard / equipment
pKa₁ / pKa₂	3.04 / 4.37 at 25 °C	potentiometric titration
Target formulation pH	3.5–4.5	pH meter with compensated electrode
Acid concentration	0.05–0.25% w/v	formulation compounding
Osmolality	270–330 mOsmol/kg	freezing-point osmometer
Sterilising filtration	0.2 μm	PVDF / PES filter
Terminal sterilisation	121.1 °C for 15 min	USP <1229.1>, Ph. Eur. 5.1.1
Incompatible ions	Ca²⁺, Mg²⁺	USP <788> particulate test

Acidulant, Buffer Component, and Preservative-Efficacy Modifier in Multidose Oral Suspensions

In multidose oral suspension manufacturing, L(+)-tartaric acid is added at 0.05–0.5% w/v to maintain the formulation pH between 3.0 and 4.5. In basic API suspensions, the protonated drug species remains dissolved in the aqueous phase, reducing sedimentation and re-dispersion defects; in acidic API suspensions, the same pH range can suppress ionisation and reduce chemical degradation. The acid is introduced as a 10% w/v stock solution into a jacketed stainless steel mixing vessel at 20–25 °C with overhead stirring at 50–150 rpm; the addition rate is set so that pH changes by no more than 0.2 pH units/min to avoid local acid pockets that can precipitate API free base or hydrolyse flavour components. In preserved oral liquids, the lower pH enhances the activity of benzoic acid because the undissociated fraction increases below pH 4.2; preservative efficacy is confirmed by Ph. Eur. 5.1.3 or USP <51> with compendial challenge organisms. The buffer capacity of tartaric acid is lower than that of citric acid at equivalent mass concentration; therefore 10–30% w/w of the acid may be replaced by sodium tartrate dihydrate to increase ionic strength and stabilise pH without exceeding the target osmolality of oral solutions. Terminal products in this segment include paediatric oral solutions, antacid suspensions, and sugar-free dry syrups that are reconstituted with purified water to a final pH of 3.5–4.5. Stability batches stored at 40 °C/75% RH for 6 months in HDPE bottles with polypropylene child-resistant closures are used to verify pH drift and preservative activity.

When tartaric acid is dry-blended into capsule fill or tablet cores as a microenvironmental pH regulator

Direct compression and capsule fill lines frequently require an acidic microenvironment without the addition of water. L(+)-tartaric acid in granular form with d₅₀ 100–250 μm is dry-blended with lactose monohydrate, microcrystalline cellulose, crospovidone, and colloidal silicon dioxide for 15–30 min in a bin blender at 10–25 rpm. The acid is added at 1–5% w/w of the core mass to achieve a slurry pH of 2.5–3.5 when the blend is dispersed in 10 mL purified water per tablet mass; this pH is measured after 10 min of stirring because dissolution of the crystalline acid is not instantaneous. The low pH modifies the dissolution of weakly basic APIs by increasing the fraction of ionised drug at the tablet surface; dissolution is evaluated with USP <711> Apparatus 2 at 50–75 rpm in 900 mL of pH 1.2, pH 4.5, and pH 6.8 media, and the pH modifier is considered effective only if the f₂ similarity criterion or single-point release specification in the dossier is met. Compression on a rotary press at 8–20 kN is used for tablets; capsule fill on an automatic dosator or tamping-pin machine is set to a fill weight range not exceeding ±3% and a plug compression height suitable for size 0–1 hard gelatin capsules. The acid can reduce powder flow due to its crystalline habit; 0.2–0.5% w/w colloidal silicon dioxide and 0.5–1.0% w/w sodium stearyl fumarate are typical flow and lubrication aids. Sticking to punch faces is observed on production lines when compression speed exceeds 80 rpm and press dwell time is below 15 ms; external lubrication and lower press speed reduce this defect. Finished oral solids in this segment include acid-modified immediate-release tablets and powder-filled capsules for weakly basic drugs, but published data for specific dosage forms is limited because the acid concentration is developed in-house.Before dry powder sachet filling into four-side-seal aluminium laminates, L(+)-tartaric acid is incorporated into non-effervescent granule formulations that require a pH-controlled reconstitution environment. The acid is milled to a particle size d₉₀ ≤ 250 μm and combined with mannitol, sodium carboxymethylcellulose, and a sweetener; the blend is granulated with 70% w/w ethanol in a fluid-bed top-spray granulator at inlet air 30–40 °C and spray rate 2–5 g/min/kg batch. After drying to a loss-on-drying value ≤ 1.0% w/w per Ph. Eur. 2.2.32, the granules are passed through an oscillating granulator with 1.0–1.5 mm screen to reduce oversize. The finished sachet is intended for reconstitution in 50 mL purified water; the acid concentration is set to 0.1–0.4 g/5 mL after reconstitution, giving a final pH of 3.0–4.2. The acidulant function is to mask metallic or bitter aftertastes of API salts and to suppress microbial growth in the reconstituted suspension if the product is used over 7–14 days; microbial limit tests follow Ph. Eur. 5.1.4 or USP <61> and USP <62>. Sachet packaging uses polyethylene terephthalate/aluminium/low-density polyethylene laminates with water vapour transmission rate ≤ 0.1 g/m²/24 h at 38 °C and 90% RH; each sachet is flushed with nitrogen to an oxygen headspace below 2% v/v. Terminal granule products include oral antibiotic dry syrups and electrolyte replacement powders, in which the acid also assists dissolution of weakly basic electrolyte salts.

Lyophilised Injectable Buffers and Oxidative Stabilisation via Tartrate Chelation Demand Strict pH Mapping

Freeze-dried parenteral products use L(+)-tartaric acid to set the pre-lyophilisation pH and to provide buffer capacity in the reconstituted solution. During bulk compounding, the acid is added to the formulation solution at 0.02–0.2% w/v and pH is adjusted to 3.0–4.5 with sodium hydroxide; the solution is then filled into borosilicate glass vials and partially stoppered. Lyophilisation is performed in a vacuum chamber with shelf temperature held at -40 °C for 2–4 h for freezing, primary drying at -20 °C to -10 °C and chamber pressure 0.05–0.15 mbar, and secondary drying at 25–35 °C until the cake moisture by Karl Fischer under Ph. Eur. 2.5.12 is ≤ 1.0% w/w. The tartrate buffer remains in the amorphous cake and dissolves rapidly upon reconstitution with WFI or 0.9% sodium chloride injection; the reconstituted pH must be within the authorised range and is tested with a calibrated pH meter. The chelation of ferric and cupric ions by tartrate is exploited in lyophilised products sensitive to metal-catalysed oxidation; the formulation must be assessed by ICH Q1A(R2) forced degradation at 25 °C/60% RH and 40 °C/75% RH for 6 months because tartrate chelation can also increase the reactivity of some iron complexes. The vial headspace is flushed with nitrogen to ≤ 2% v/v oxygen before sealing; elastomeric closures are selected for low moisture and oxygen permeability. Incompatibility with calcium-containing diluents remains operational; the label storage condition is typically 2–8 °C for lyophilised tartrate-buffered products unless the dossier supports 25 °C storage. Published data for this specific configuration is limited for some APIs, and the final pH and moisture limits are product-specific.